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ABSTRACT 42 
Objective 43 
To determine what  issues are experienced during the first few weeks of therapy by patients, and 44 
their parents/carers, when a child/young person has been prescribed a new  medicine.  45 
Method 46 
One-hundred patients aged ≤18 years of age prescribed a new  medicine for ≥ 6 weeks were 47 
recruited from a single United Kingdom National Health Service (NHS) specialist paediatric hospital 48 
out-patient pharmacy.  Six weeks after the first dispensing of their new medicine the patient or their 49 
parent/carer received telephone follow-up by a researcher and verbally completed a questionnaire 50 
containing both open and closed questions.  Patient or parent/carer experiences were identified and 51 
analysed using thematic analysis and descriptive statistics.     52 
Results 53 
Eighty-six participants were available for telephone follow-up.  Six (7%) had not started their 54 
medicine.    Paediatric patients and their parents/carers experienced a range of issues during the 55 
first few weeks after starting a new medicine.  These included additional concerns/questions (24/80, 56 
30%), administration issues (21/80, 26.3%), adverse effects (29/80, 36.3%) and obtaining repeat 57 
supplies (12/80, 15%).  The Morisky Medication Adherence Scale indicated that 34/78 (43.6%) 58 
participants had a high adherence rating, 35/78 (44.9%) medium and 9/78 (11.5%) a low rating.   59 
Conclusion 60 
Paediatric patients and their parents/carers experience a range of issues during the first few weeks 61 
after starting a new medicine.  Further research is required to determine the type of interventions 62 
that may further support medicines use in this group of patients. 63 
 64 
Key Words 65 
 66 
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 68 
Key Messages 69 
What is already known on this subject: 70 
 Little is known about the experiences of paediatric patients, and their parents/carers, during 71 
the first few weeks after child has started a new  medicine.  72 
What this study adds: 73 
 This study has shown that children, and their parents/carers, experience a range of issues 74 
during the first 6 weeks after starting a new  medicine. 75 
 These issues include concerns/questions, information requirements, adverse effects, 76 
arranging further supplies and adherence.   77 
 Interventions to support medicine taking during this period may optimise medicines use in 78 
this group of patients.  79 
 80 
 81 
 82 
 83 
 84 
 85 
 86 
INTRODUCTION 87 
 88 
People prescribed self-administered medicines typically take about half their doses.[1] Efforts to 89 
assist patients with adherence might improve the benefits of prescribed medicines. 90 
 91 
Medicines taking in children may be influenced by parents/carers beliefs about the condition, 92 
treatment regimen, child resistance, relationships within families, desire to preserve normal life and 93 
input from health professionals.[2]  94 
 95 
A recent study of the experiences of medicine-related issues encountered by parents/carers of 96 
paediatric liver transplant patients found they reported problems obtaining their medicine, 97 
administering the medicines and side effects (including insufficient knowledge of side effect 98 
management).[3] 99 
 100 
A review of the medical notes of 11 – 18 year old patients with juvenile arthritis found that despite 101 
the increasing complexity of drug regimens major gaps existed in the documentation of knowledge 102 
and skills relevant to the self-management of such regimens by patients.[4]   103 
 104 
Barber et al, in a study of adult patients started on chronic medicines, found they quickly became 105 
non-adherent and identified a number of medicine related problems and information needs.[5]  106 
These included side effects, concerns about taking a new medicine, swallowing difficulties and 107 
remembering the regimen.  In response to these issues the National Health Service (NHS) funded 108 
New Medicines Service (NMS) was established in England in 2011.[6]  This is a medication review 109 
delivered through community pharmacists to support people with long-term conditions newly 110 
prescribed a medicine.  The NMS improves adherence by 10% and increases the number of 111 
medicines problems identified and resolved.[7]  Improved medication adherence has been shown to 112 
improve disease outcomes in children with cystic fibrosis[8], asthma[9] and renal disease.[10]  113 
However, the NMS  may not be available to children and cannot be undertaken with a  114 
parent/carer.[6]   115 
 116 
The rationale of medication review could apply to children with chronic diseases.[11]  Issues such as 117 
polypharmacy, wastage and medicine-related problems are likely to be similar to those in adults.  118 
However, a literature review, using AMED, British Nursing Index, CINAHL, EMBASE, HMIC, MEDLINE, 119 
PsycINFO and Health Business Elite, did not identify any studies of medication review specific to 120 
children.  Recently, the UK National Institute for Health and Care Excellence (NICE) recommended 121 
further research concerning medication review in children, including minimising medicines related 122 
problems.[12]  Other initiatives that may optimise medicines use include better partnerships with 123 
patients, telephone helplines, internet support websites and improving collaboration between 124 
healthcare professionals.[13]    125 
 126 
The present study focused on the experiences of patients and their parents/carers during the first 127 
few weeks after a paediatric patient began taking a new  medicine.   128 
 129 
Aim 130 
 131 
To determine what medicine-related issues are experienced during the first few weeks of therapy by 132 
patients, and their parents/carers, when a child/young person has been prescribed a new  medicine.  133 
 134 
Ethical Approval 135 
 136 
The study was approved by Yorkshire and Humber –Sheffield, UK, National Research Ethics Service 137 
24/09/14 (REC reference 14/YH/1086, IRAS project ID 148123).  138 
 139 
METHOD 140 
 141 
Setting 142 
 143 
The study was undertaken at a specialist UK paediatric hospital (34 specialties, 361 beds, over 144 
174,000 out-patient visits per year).[14]  145 
 146 
Participant Recruitment 147 
 148 
Potential participants were identified through presentation of a prescription to the out-patient 149 
pharmacy which met the study inclusion criteria.  Consent and recruitment were undertaken by  150 
pharmacists based in the hospital’s out-patient pharmacy whilst the participant waited for their 151 
prescription.  Written consent was taken from the patient’s parent/carer if the child was under 16 152 
years or the patient if 16 years or older.  An assent form was used for patients  aged 12 – 15 years 153 
and was signed by the patient alongside the parent/carer consent form.  Age related participant 154 
information leaflets were provided.  To minimise impact on service delivery a convenience sample of 155 
participants were recruited during the period February to July 2015.  This study was exploratory and 156 
the authors considered a recruitment number of 100 participants would provide sufficient range of 157 
specialities and participants to identify important findings.  There were no known published studies 158 
to guide recruitment numbers. 159 
 160 
Inclusion Criteria 161 
 162 
Participant inclusion criteria were: ages 0-18 years; prescribed a new medicine to be taken for 6 163 
weeks or longer; access to a telephone for follow-up; not receiving medication for a life-limiting 164 
condition; could understand written and spoken English.  The authors considered a period of 6 165 
weeks to have provided the patient, and their parent/carer, sufficient experience of taking the new 166 
medicine prior to follow-up. 167 
 168 
Data Collection 169 
 170 
Demographic information was recorded from the patient’s prescription: medical/surgical clinic 171 
attended, age/gender of the patient, medicine prescribed and therapeutic indication.  172 
 173 
A questionnaire containing both open and closed questions was used as the research instrument.  174 
This was completed by telephone with direct support from the lead study researcher.  Cognisant 175 
testing of the questionnaire was assessed with a parent of a child taking long-term medicines and 176 
piloted with 5 participants.  Six weeks following the dispensing of their new medicine participants 177 
received telephone follow-up by the study lead researcher.  Participants were asked: whether they 178 
had researched further information about the new medicine themselves and why, any 179 
concerns/questions occurring over the previous 6 weeks, if they had experienced any problems 180 
taking/administering the medicine, whether they had experienced adverse effects from their new 181 
medicine and any problems arranging repeat supplies.  Participants’ adherence was assessed using 182 
the Morisky Medication Adherence Scale (MMAS-8).[15]     183 
 184 
Responses were transcribed in real time by the researcher during the interview.  185 
 186 
Data Analysis 187 
 188 
Responses were analysed using thematic analysis.  The responses were listed, grouped by 189 
similar/related theme and coded.  Collated responses were analysed using NVivo version 10.  190 
Quantitative results were analysed using descriptive statistics using The Statistical Package for Social 191 
Sciences (SPSS) version 22.         192 
 193 
RESULTS 194 
 195 
Demographic Information 196 
 197 
One hundred participants were recruited to the study.  Fifty-one patients were female and 49 male 198 
with a mean age of 8 years (range 0.33 years - 17 years).  Patients were managed by one of 15 199 
specialities (Table 1).   200 
 201 
Table 1 Specialities 202 
Speciality N 
General Paediatrics 23 
Ear, Nose and Throat 14 
Neurology 13 
Dermatology 10 
Urology 9 
Respiratory 7 
Rheumatology 5 
Emergency Department 3 
Gastroenterology 3 
Hepatology 3 
Nephrology 3 
Ophthalmology 3 
Cardiology 2 
Inherited Metabolic Diseases 1 
Plastics  1 
  203 
In total 145 medicines were prescribed which patients had not previously received (Table 2).      204 
 205 
Table 2 Medicines Prescribed for Study Participants 206 
Therapeutic Use Number of 
Medicines (%) 
Medicine (n) 
Eczema 27 (18.6%) Topical corticosteroid (13) 
Emollient (7) 
Dressings (3) 
Hydroxyzine (2) 
Potassium Permanganate (1) 
Topical tacrolimus (1) 
Asthma 17(11.7%) Beclometasone (6) 
Montelukast (4) 
Fluticasone (2) 
Fluticasone/Salmeterol (2) 
Salbutamol (2) 
Ipratropium (1) 
Allergy 14(9.7%) Fluticasone (8) 
Cetirizine (2) 
Adrenaline (1) 
Chlorphenamine (1) 
Desloratadine (1) 
Nutramigen (1) 
Urinary 
Frequency/Enuresis 
14 (9.7%) Desmopressin (6) 
Oxybutynin (6) 
Tolterodine (2) 
Migraine/Headache 11(7.6%) Pizotifen (6) 
Propranolol (2) 
Sumatriptan (2) 
Migraleve (1) 
Gastro-0esophageal  
Reflux 
9 (6.2%) Ranitidine (7) 
Lansoprazole (1) 
Omeprazole (1) 
Epilepsy 8 (5.5%) Levetiracetam(2) 
Acetazolamide (1) 
Carbamazepine (1) 
Lamotrigine (1) 
Sodium valproate (1) 
Stiripentol (1) 
Topiramate (1) 
 207 
 208 
 209 
 210 
 211 
Therapeutic Use Number of 
Medicines 
(%) 
Medicine (N) 
Infection 8(5.5%) Trimethoprim (3) 
Amoxicillin (1) 
Azithromycin (1) 
Co-trimoxazole (1) 
Erythromycin (1) 
Itraconazole (1) 
Constipation 6 (4.1%) Macrogols (5) 
Senna (1) 
Vitamins 6 (4.1%) Colecalciferol (2) 
Folic Acid (2) 
Alfacalcidol (1) 
Ergocalciferol (1) 
Rheumatic diseases 5 (3.4%) Nifedipine (2) 
Piroxicam (2) 
Hydroxychloroquine (1) 
Immunosuppression 4 (2.8%) Azathioprine (2) 
Ciclosporin (1) 
Methotrexate (1) 
Cardiovascular 3 (2.1%) Atorvastatin (1) 
Enalapril (1) 
Losartan (1) 
Ophthalmic 3(2.1%) Prednisolone (2) 
Fluorometholone (1) 
Cholestasis 2 (1.4%) Ursodeoxycholic acid (2) 
Emesis 2 (1.4%) Ondansetron (2) 
Other 6 (4.1%) Amitriptyline (1) 
Colestyramine (1) 
Dexamethasone/framycetin/gramicidin (1) 
Levomepromazine (1) 
Melatonin (1) 
Propranolol (1) 
 212 
Eighty-six participants received telephone follow-up.   Follow-up was undertaken with 83 (96.5%) 213 
parents/carers and 3 (3.5%) young people (two aged 16 years and one 14 years following parental 214 
consent).  Fourteen participants were not contactable. 215 
 216 
Adherence to the Prescribed Regimen 217 
 218 
Telephone follow-up revealed that 6 (7%) patients had not taken their medicine.  Two 219 
parents/carers were concerned about side effects (macrogol and topical corticosteroid), 2 had not 220 
required their medicine (chlorphenamine, pizotifen and sumatriptan), 1 patient refused to be 221 
administered a macrogol suspension and 1 patient was concerned about how nifedipine would 222 
interact with her other medicines. 223 
 224 
“I read the leaflet that it came with then decided to try naturally.  I haven’t started her on it yet.  225 
They said that she wasn’t drinking enough.  I pushed the fluids, she’s been better than she was.  It 226 
can cause diarrhoea and I didn’t want to send her the other way…” Parent of Patient 18 (macrogol) 227 
 228 
“I haven’t been taking it because I couldn’t find out if it was compatible with my other medicines.  I’m 229 
doing my exams at the moment, I didn’t think it would be very smart to take them.” Patient 46 230 
(nifedipine) 231 
 232 
The MMAS-8 was used to determine self-reported adherence.  Thirty-four (43.6%) scored zero 233 
indicting high adherence, 35 (44.9%) scored 1-2 indicating medium adherence and 9 (11.5%) had a 234 
score >2 indicating low adherence.  Two participants were receiving medicine that was used on a 235 
‘when required’ basis and thus were excluded from the analysis.   236 
 237 
Four (5%) participants had purchased medicine compliance aids. 238 
 239 
 “We were advised to take it with or after food.  If I’d forgotten I didn’t know if I could then give it 240 
and so I would miss the dose and give his next one.” Patient 61 (ursodeoxycholic acid) 241 
 242 
“I don’t find it difficult to stick to the plan because I know we have to stick to it because it’s for his 243 
eyes.  A bit inconvenienced…it blows his weekend out.  We give it on a Saturday morning so we can 244 
do something on a Friday night if we want to.  I sometimes forget the folic acid as he has three days 245 
off when he’s on the methotrexate.”  Parent of Patient 20 (methotrexate) 246 
 247 
Eighteen (22.5%) participants intentionally omitted doses.  These were due to adverse effects (5, 248 
27.8%), concurrent acute illness (3, 16.7%), timing of administration (3, 16.7%), the desire to look up 249 
more information before starting the medicines (2, 11.1%), incorrect use (2, 11.1%), child declining 250 
to take (1, 5.6%), a mother not wanting their child to have the medicine as, although not used for 251 
this indication, they were an antidepressant (1, 5.6%) and ran out of supplies (1, 5.6%). 252 
 253 
“He was poorly once and was taking Calpol, Nurofen and antibiotics.  So I stopped giving it then as I 254 
thought it was a bit much.” Parent of Patient 100 (ranitidine) 255 
 256 
“Only the first night because of reading the side effects.  My husband looked on the internet.  Then 257 
we read the information the doctor gave us and realised it was more related to children and my 258 
husband was much happier so we gave it.” Parent of Patient 56 (desmopressin) 259 
 260 
Seeking Further Information 261 
 262 
Twenty-six (30.2%) participants sought further information about their medicine.   Twenty-two 263 
participants (84.6%) searched the internet, 2 (7.7%) asked a friend/relative, 1 (3.8%) asked other 264 
parents and 1 (3.8%) had looked in the British National Formulary.   265 
 266 
Participants sought further information to: find out about side effects (13, 50%), general interest (5, 267 
19.2%), reassurance about the appropriateness of treatment (4, 15.4%), research a specific query (3, 268 
11.5%) and check that there were no interactions with concomitant medicine(s) (3, 11.5%). 269 
 270 
“I’m giving something new.  I want to know what side effects there are.  [Patient 6] is on lots of 271 
medicines, she’s having seizures and I want to see how it interacts with the others, I don’t want to 272 
make these worse.” Parent of Patient 6 (levomepromazine) 273 
 274 
“Basically, is that the right drug?  Is it common to use it at this stage?” Parent of Patient 75 275 
(azathioprine) 276 
 277 
Concerns and Further Questions 278 
 279 
Twenty-four (30%) participants who had taken/administered their medicine had some concerns.  280 
These related to side effects (10, 41.7%), efficacy (6, 25%), administration (4, 16.7%) and other 281 
concerns (4, 16.7%).  Other concerns were the: perceived stigma of taking an antidepressant, impact 282 
of a friend questioning the choice of therapy, anticipated repeat prescription problems through the 283 
General Practitioner (GP) and advice provided by a pharmacist.   284 
 285 
“There was one thing.  My friend works in a hospital, I’m not sure what she does, but when she saw 286 
what [Patient 11] was on she said that they’d been told to stop using them.  I don’t know why that 287 
is.” Parent of Patient 11 (piroxicam)   288 
 289 
Administration Issues 290 
 291 
Issues regarding administration were experienced by 21 (26.3%) participants.  These were issues 292 
concerning:  dislike of the taste/smell (11, 52.4%), timing of administration (3, 14.3%) and the impact 293 
of autism/learning difficulties (2, 9.5%).  Other (5, 23.8%) experiences included the: manipulation of 294 
a tablet to obtain a part-dose, problems extracting a tablet from a blister pack, fear of an inhaled 295 
spacer device, absence of a bottle adapter and swallowing difficulties.    296 
 297 
“It was difficult to find a suitable time as needed to be taken on an empty stomach an hour before 298 
food.  She took it at school as there’s no afternoon break.  In the morning she has breakfast, then 299 
there’s lunchtime.  When she comes home she has an evening meal and then she’s tired and it’s time 300 
for bed.” Parent of Patient 23 (lansoprazole) 301 
 302 
“He’s got a new spacer now as he couldn’t cope with the big one.  It scared him.  He’s got a smaller 303 
one with bears on it now which is fine from the GP.” Parent of Patient 33 (beclomethasone inhaler) 304 
 305 
Adverse Effects 306 
 307 
Whilst cause and effect was not established, adverse effects were reported by 29 (36.3%) 308 
participants (Table 3).  309 
   310 
“Upper abdominal pain under her rib cage for three weeks, periodic headache, exhausted, very, very 311 
tired, her menstrual cycle has gone haywire.  She’s been off school for three weeks.  I’m desperate to 312 
find out the cause to alleviate her symptoms.  My head tells me it’s the side effects from the drug…” 313 
Parent of Patient 15 (ciclosporin) 314 
“I was told one of the side effects was increased appetite.  But her appetite is much greater now.  I 315 
didn’t realise just how much it would increase.” Parent of Patient 30 (pizotifen) 316 
 317 
Table 3 Reported Adverse Effects 318 
Therapeutic Use Medicine Number of 
Patients 
Reporting 
Effect 
Reported Adverse 
Effect(s) 
Eczema Topical corticosteroid 1 Staining of clothing. 
Hydroxyzine  1 Drowsiness 
Allergy Fluticasone 2 Nose bleed, sore throat 
Urinary 
Frequency/Enuresis 
Oxybutinin  2 Drowsiness, dry mouth. 
Tolterodine 2 Drowsiness, dry mouth, 
constipation, abdominal 
pain.  
Migraine/Headache 
 
Pizotifen  3 Behavioural changes, 
constipation, increased 
appetite. 
Propranolol 1 Fatigue 
Gastro-Oesophageal  
Reflux 
Ranitidine  1 Vomiting 
Epilepsy Levetiracetam 2 Behavioural changes 
Acetazolamide  1 Behavioural changes 
Lamotrigine  1 Suicidal ideation 
Constipation Marogol 1 Diarrhoea 
Rheumatic diseases 
 
Nifedipine 1 Nausea, dizziness. 
Hydroxychloroquine 1 Abdominal pain. 
Immunosuppression 
 
Azathioprine 2 Blacking out/fainting, 
hairloss. 
Ciclosporin 1 Abdominal pain, 
headache, fatigued, 
changes to menstrual 
cycle.   
Methotrexate 1 Abdominal pain. 
Other Amitriptyline 1 Drowsiness 
Atorvastatin 1 Jaundice 
Enalapril 1 Dry cough 
Itraconazole 1 Abdominal pain. 
Propranolol 1 Coldness of the 
extremities 
 319 
Further Supply Issues 320 
Twelve (15%) participants experienced difficulties obtaining further supplies.  Forty-seven 321 
participants (58.8%) had sufficient supplies from the hospital and 21 (26.3%) obtained further 322 
supplies from their GP.  The problems experienced by participants included: delays in posting out 323 
clinic letters to the GP (4, 33.3%), insufficient information on the letter for a repeat prescription (3, 324 
25%), insufficient quantities prescribed by the GP (2, 16.7%), misreading of a letter by the GP (1, 325 
8.3%), cancellation of a follow-up out-patient appointment where a repeat prescription was to be 326 
provided (1, 8.3%) and confusion due to a therapy substitution by the hospital pharmacy which did 327 
not then match the information in the clinic letter (1, 8.3%). 328 
 329 
“Yes, there was some confusion between the doctors.  The hospital hadn’t written to the GP, the 330 
letter hadn’t been sent so I had to phone the consultant who organised the letter.  Missed a week of 331 
the antibiotic.” Parent of Patient 26 (co-trimoxazole) 332 
 333 
“Ran out of tablets.  The doctor said to take the course and we’ll see you back.  Out-patient on 8th 334 
June cancelled by the hospital and arranged for much later in August.  Had to phone up and get it 335 
brought forward.  The doctor said to take it for 6 weeks.  We only had a 4 week supply.” Parent of 336 
Patient 45 (amitriptyline) 337 
 338 
DISCUSSION 339 
 340 
Patients have a right to decide not to take their medicine and may have different views about risks, 341 
benefits and side effects.[16]  In this current study, 6/86 (7%) participants had not started their 342 
medicine and 18/80 (22.5%) participants had intentionally omitted some doses.  Therefore some are 343 
reviewing the initial therapy decision and others are making treatment changes without consulting a 344 
healthcare professional.  Shared decision making between clinicians and patients about treatment 345 
choice is important.[17]  Poor communication may lead patients to obtain information outside of a 346 
consultation with a healthcare professional.[18]   347 
 348 
Overall participant reported adherence in this study was comparable with that published in the 349 
paediatric literature.[19, 20]  Thirty-four (43.6%) participants exhibiting high adherence and 35 350 
(44.9%) medium adherence.  Four (5%) participants had purchased medicine compliance aids.  Due 351 
to a lack of beneficial outcomes with the use of compliance aids the UK Royal Pharmaceutical Society 352 
recommends original pack dispensing with appropriate pharmaceutical care including clinical 353 
medication review.[21] 354 
 355 
A recent systematic review identified a number of findings that contribute to explaining treatment 356 
adherence in paediatrics.[2]  Including beliefs about the condition or treatment, treatment regimen 357 
and child resistance.  Findings from the present study were consistent with these.  For example 3/86 358 
(3.5%) participants decided against treatment, 21/80 (26.3%) experienced issues with administration 359 
including the taste/smell of the medicine and timing of administration.  Whilst the systematic 360 
review[2] focussed on long-term conditions it did not identify when during treatment these themes 361 
occurred.  This current study found that they can occur within the first six weeks after starting a new 362 
medicine. 363 
 364 
A study of adult patients prescribed a new long-term medicine found that once a patient has 365 
experienced their medicine, they gain some knowledge of what it does and new questions arise.[5]  366 
The current study has shown that children and their parents/carers have similar experiences after 367 
the first few weeks of therapy.  This is illustrated by 26/86 (30.2%) participants researching further 368 
information about their new medicines, 24/80 (30%) having concerns or further questions and 29/80 369 
(36.3%) possibly experiencing an adverse effect to treatment.  370 
 371 
Twenty-one (26.3%) parents/carers had difficulties administering the medicine to their child.  In 372 
adults, oral solid dosage forms are mostly acceptable.  However, potential paediatric patients may 373 
include neonates, toddlers, young children and adolescents, and hence will have widely varying 374 
needs.[22] A change in formulation is currently excluded from triggering a NMS consultation.[23]Any 375 
future paediatric medication review should include changes in formulation as a trigger for a 376 
medication review.   377 
 378 
Current evidence suggests that when patients move between care providers the risk of 379 
miscommunication and unintended changes to medicines is a significant problem.[24]  This current 380 
study suggests that this is an issue in paediatrics with 12 (15%) participants experiencing problems 381 
arranging a repeat supply with 7 (58.3%) due to a miscommunication.   382 
 383 
A systematic review of interventions to improve the safe and effective use of medicines by 384 
consumers identified a scarcity of evidence in children/young people.[25] The benefits of a 385 
medication review through the NMS have been appraised.[7]  The NMS appraisal identified a variety 386 
of factors impacting on adherence including forgetfulness, beliefs about treatment necessity, stigma, 387 
lack of peer/family support, lack of knowledge, side effects, fear of dependency, regimen 388 
complexity, inability to use the formulation and access to medicines.  Each of these factors were 389 
identified in this current study. The NMS applies a structured approach to identifying and resolving 390 
these issues.[7, 23]   However it  may not be available to children and is not available to  their 391 
parents/carers.[6]   392 
 393 
The results of this current study suggest that paediatric patients and their caregivers may benefit 394 
from some support initiative  after the first few weeks of treatment with one option being an NMS 395 
type intervention.  In addition to medication review a number of other initiatives may further 396 
support patients realising the benefits of their medicines.  These include fostering better 397 
partnerships with patients, the use of telephone helplines for information on medicines, developing 398 
specific internet support websites, and improvements to how different healthcare professionals 399 
collaborate together.[13]    400 
 401 
 402 
 403 
The limitations of this study include sample size which was relatively small, specialist paediatric 404 
centre setting which may limit how generalisable the results are and the restriction to English 405 
language speakers.    406 
 407 
     408 
 409 
Conclusion 410 
 411 
Paediatric patients and their parents/carers experience a range of issues during the first six weeks 412 
after starting a new medicine.  Intervention  at this stage may provide useful support to both the 413 
patient and their parent/carer.  Further research is required to determine the type of intervention 414 
and how it could be integrated in to practice to optimise paediatric medicine use. 415 
 416 
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